VistaGen Therapeutics, Inc. Earnings Recaps
Q3 2026
Feb 13, 2026
Vistagen Therapeutics reported significant progress in its clinical-stage programs, highlighted by the completion of the PALISADE-3 Phase III trial and continued advancements in its women's health product candidate, refisolone.
Key takeaways
- Completed the randomized portion of the PALISADE-3 Phase III trial focused on social anxiety disorder, with ongoing enhancements for the PALISADE-4 trial.
- Received USAN adoption for refisolone, a hormone-free treatment candidate for menopause-related symptoms, with an IND submission planned for H1 2026.
- Cash position stands at $61.8 million, supported by company-wide cash preservation measures to ensure operational efficiency and strategic flexibility.